Astellas’ Myrbetriq ER Patent Revived as Fed. Cir. Chides Judge

The Federal Circuit vacated a decision axing an Astellas Pharma Inc. drug patent based on an argument not presented at trial and chastised the federal judge in Delaware who issued it. “By rendering its decision on a ground not raised by any
Read more...